Talzenna Approved By FDA, Bringing New Targeted Treatment Options To Breast Cancer Patients
In October 2018, the U.S. Food and Drug Administration (FDA) approved talazoparib, a novel PARP inhibitor, for the treatment of patients with HER2-negative locally advanced or metastatic breast cancer harboring mutations in the BRCA gene.…